Search Within

Dana Elizabeth Rathkopf

  1. "2014"
Formats
  1. Meeting Abstract (15)
  2. Journal Article (6)
Groups
  1. Department of Medicine (21)
  2. Genitourinary Oncology Service (21)
  3. Solid Tumor Oncology Division (21)
  4. GSK Faculty (3)
  5. Hematologic Malignancies, Division of (3)
  6. Human Oncology and Pathogenesis Program (3)

More Groups

People
  1. Howard Scher (13)
  2. Michael Morris (5)
  3. Brett Carver (3)
  4. Daniel Danila (3)
  5. Susan Slovin (3)
  6. Yu Chen (3)

More People

Years
  1. 2014 (21)
Publications
  1. Journal of Clinical Oncology (13)
  2. Annals of Oncology (1)
  3. BJU International (1)
  4. Cancer Research (1)
  5. Cell (1)
  6. Current Clinical Urology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (13)
  2. American Association for Cancer Research (1)
  3. C M P Medica LLC * The Oncology Group (1)
  4. Cell Press (1)
  5. Elsevier Science, Inc. (1)
  6. Humana Press Inc (1)

More Publishers

Results (21)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The androgen receptor as a therapeutic target for castration-resistant prostate cancer
    Journal Article

    Feldman, J. L.; Rathkopf, D.; Morris, M. J.
    Current Clinical Urology (2014)

    Fulltext@MSK | Save
  • Establishing a neoadjuvant platform for developing targeted agents: Degarelix prior to prostatectomy for patients with intermediate- and high-risk prostate cancer
    Meeting Abstract

    Touijer, K. A.; Carver, B. S.; Coleman, J. A.; Laudone, V. P.; Hullings, M.; Ehrlich, S. S.; DeNunzio, M.; Reuter, V. E.; Eastham, J. A.; Danila, D. C.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Predicting response to abiraterone acetate (AA): mRNA biomarker analysis of study COU-AA-302
    Meeting Abstract

    Ricci, D. S.; Li, W. M.; Griffin, T. W.; Gormley, M.; Henitz, E.; Ryan, C. J.; de Bono, J. S.; Attard, G.; Van Den Eertwegh, A. J. M.; Schrijvers, D. L.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment
    Meeting Abstract

    Rathkopf, D. E.; Antonarakis, E. S.; Shore, N. D.; Tutrone, R. F.; Alumkal, J. J.; Ryan, C. J.; Saleh, M. N.; Hauke, R. J.; Bandekar, R.; Maneval, E. C.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Targeting reciprocal feedback inhibition in the clinic: ARN509 and PI3K pathway inhibition in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Carver, B. S.; Chen, Y.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Autio, K. A.; DeNunzio, M.; Sawyers, C. L.; Scher, H. I.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo
    Meeting Abstract

    Morris, M. J.; Loriot, Y.; Beer, T. M.; Higano, C. S.; Armstrong, A. J.; Sternberg, C. N.; de Bono, J. S.; Tombal, B. F.; Noonberg, S. B.; Mansbach, H. H.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel
    Meeting Abstract

    Joshua, A. M.; Shore, N. D.; Saad, F.; Chi, K. N.; Olsson, C. A.; Emmenegger, U.; Scholz, M. C.; Berry, W. R.; Mukherjee, S.; Winquist, E.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Armstrong, A. J.; Tombal, B.; Sternberg, C. N.; Higano, C. S.; Rathkopf, D. E.; Loriot, Y.; Saad, F.; Joshua, A. M.; de Bono, J. S.; Venner, P. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (AA)
    Meeting Abstract

    Rathkopf, D. E.; Antonarakis, E. S.; Shore, N. D.; Tutrone, R.; Alumkal, J. J.; Ryan, C. J.; Saleh, M. N.; Hauke, R. J.; Bandekar, R.; Maneval, E. C.; more...
    Cancer Research (2014)

    Fulltext@MSK | Save
  • Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (MCRPC) patients (pts) without prior chemotherapy
    Meeting Abstract

    Ryan, C. J.; Smith, M. R.; Fizazi, K.; Miller, K.; Mulders, P.; Sternberg, C. N.; Saad, F.; Griffin, T.; De Porre, P.; Park, Y. C.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save